# HBM-MedFocus

> HBM-MedFocus is a VC fund in Irvine backing Medical Device, Health Care and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Irvine, United States
- Total investments: 5
- Last investment: Mar 2024
- Lead investor: 60%
- Last updated: Aug 2026
- Website: https://www.medfocusfunds.com/

HBM-MedFocus is a venture capital fund managed by MedFocus Fund.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5M–$26M |
| Series B | $17M–$18M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 80% |
| Health Care | 3 | 60% |
| Therapeutics | 3 | 60% |
| Biotechnology | 3 | 60% |
| Medical | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Ireland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Shape Memory Medical | Shape Memory Medical Inc is a medical device company based in Santa Clara, California, founded to commercialize innovative medical devices based on Shape Memory Polymer (SMP) materials that were developed at Texas A&M University and Lawrence Livermore National Laboratory. The company is dedicated to developing innovative therapeutic solutionsfor peripheral vascular, cardiovascular, and neurovascular markets.Shape Memory Medical's device is the first to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology to a vascular market, enabling physicians to improve patient care. The Shape Memory Medical team has extensive experience with the SMP foam technology and the commercialization of medical devices. | $38M | Series C | Mar 04, 2024 |  |
| Perfuze | Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway. | $25.7M | Series A | Feb 07, 2022 |  |
| Viseon | Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation. | $18M | Series B | Feb 25, 2020 |  |
| Viseon | Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation. | $5M | Series A | Sep 26, 2017 |  |
| Rebound Therapeutics | Rebound has progressed rapidly over the past 18 months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive surgical procedures. In addition to rapid product development of its initial products, Rebound has assembled a world-class Scientific Advisory Board of leading MIS physicians,filed 14 patents to solidify its intellectual property platform and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon. | $16.5M | Series B | Jul 25, 2017 |  |

5 of 5 investments shown.

## Co-investors
- [Wexford Capital](https://shizune.co/investors/profile/wexford-capital) — VC Fund, 4 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 3 deals together
- [EarlyBird](https://shizune.co/investors/profile/earlybird-3) — VC Fund, 1 deal together
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 1 deal together
- [Emergent Medical Partners](https://shizune.co/investors/profile/emergent-medical-partners) — VC Fund, 1 deal together
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [Biotech Investors in Ireland](https://shizune.co/investors/biotech-investors-ireland)
- [Biotech VC Funds in Ireland](https://shizune.co/investors/biotech-vc-funds-ireland)
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Medical Device VC Funds in Ireland](https://shizune.co/investors/medical-device-vc-funds-ireland)

## FAQ

### What does HBM-MedFocus invest in?

HBM-MedFocus invests primarily in Medical Device, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is HBM-MedFocus's check size?

HBM-MedFocus typically joins rounds of $5M–$26M at Series A and $17M–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HBM-MedFocus participates in.

### When did HBM-MedFocus last invest?

The most recent investment recorded for HBM-MedFocus closed in Mar 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co